I think Invion has done all it can with this drug by demonstrating a dose/response relationship and presenting safety at much higher doses than those trialled earlier. The market is not excited and I think Invion need to organise a partner for some dollars to progress their inhaled business. Bring on the nadolol studies and quickly please because I prefer to see green on my screen not red.
Ann: INV103 ala-Cpn10 clinical trial in lupus complete, page-12
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $13.53M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.2¢ | $52.22K | 17.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 55 | 54807402 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 8956699 | 13 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| IVX (ASX) Chart |